References
- Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other gram-negative bacteria. Infect Dis Ther. 2021;10(1):75–92. doi:10.1007/s40121-020-00395-2
- Jean SS, Harnod D, Hsueh PR. Global Threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. doi:10.3389/fcimb.2022.823684
- Karaiskos I, Galani I, Souli M, Giamarellou H. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15(2):133–149. doi:10.1080/17425255.2019.1563071
- Tan X, Kim HS, Baugh K, et al. Therapeutic options for metallo-β-lactamase-producing enterobacterales. Infect Drug Resist. 2021;14:125–142. doi:10.2147/IDR.S246174
- Marshall S, Hujer AM, Rojas LJ, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017;61(4):e02243–16. doi:10.1128/AAC.02243-16
- Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878. doi:10.1093/cid/ciaa586
- Yu W, Xiong L, Luo Q, et al. In vitro activity comparison of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections with carbapenem-resistant organisms in China. Front Cell Infect Microbiol. 2021;11:780365. doi:10.3389/fcimb.2021.780365
- Sadek M, Juhas M, Poirel L, Nordmann P. Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-β-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother. 2020;64(12):e01659–20. doi:10.1128/AAC.01659-20
- Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR, Bhatti MM. Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother. 2021;65(11):e0084621. doi:10.1128/AAC.00846-21
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Wayne, PA, USA: CLSI supplement M100; 2020.
- Liu Z, Gu Y, Li X, et al. Identification and Characterization of NDM-1-producing hypervirulent (Hypermucoviscous) Klebsiella pneumoniae in China. Ann Lab Med. 2019;39(2):167–175. doi:10.3343/alm.2019.39.2.167
- EUCAST. Zone diameter Breakpoint Tables for rapid antimicrobial susceptibility testing (RAST) directly from blood culture bottles. Version 5.0; 2022. Available from: http://www.eucast.org. Accessed March 7, 2023.
- Bhatnagar A, Ransom EM, Machado MJ, et al. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales. J Antimicrob Chemother. 2021;76(4):979–983. doi:10.1093/jac/dkaa531
- Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg301
- Simner PJ, Bergman Y, Trejo M, et al. Two-site evaluation of the colistin broth disk elution test to determine colistin in vitro activity against gram-negative bacilli. J Clin Microbiol. 2019;57(2):e01163–18. doi:10.1128/JCM.01163-18
- Humphries RM, Green DA, Schuetz AN, et al. Multicenter evaluation of colistin broth disk elution and colistin agar test: a report from the clinical and laboratory standards institute. J Clin Microbiol. 2019;57(11):e01269–19. doi:10.1128/JCM.01269-19
- Shang H, Wang YS, Sheng ZY. National Guide to Clinical Laboratory Procedures. Beijing: People′s medical publishing house; 2015:574–578.